Capricor Therapeutics Inc
Capricor Therapeutics Inc (CAPR) is a clinical‑stage biotechnology company focused on developing cell- and exosome-based therapies for cardiac and neuromuscular conditions. It pursues treatments aimed at heart repair and rare diseases, with a small market capitalisation of about $291.22 million, which typically points to relatively low liquidity and higher share-price volatility. Key investment considerations include binary clinical outcomes, lengthy regulatory and development timelines, manufacturing complexity and the usual biotech risks such as trial setbacks and funding needs. For investors, Capricor may offer upside if trials succeed, but losses are possible and time horizons can be long. This summary is educational and not personal financial advice; investors should review the company’s regulatory filings, trial data and consult a qualified adviser to assess suitability for their portfolios.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Capricor Therapeutics stock, with a target price indicating significant growth potential.
Financial Health
Capricor Therapeutics is generating modest revenue and cash flow, indicating stable financial operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CAPR
Gene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketDavid Vs. Goliath
This carefully curated selection features ambitious companies challenging industry giants with innovative strategies. Our experts have identified these potential disruptors that leverage cutting-edge technology and smarter business models to take on established market leaders.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
Progress hinges on trial readouts and regulatory milestones, which can create sharp share-price moves; outcomes are uncertain and timelines can be long.
Rare disease potential
Targeting cardiac and neuromuscular conditions can offer significant unmet-need opportunities, though commercial success depends on safety, efficacy and reimbursement paths.
High-risk profile
Small market cap and development-stage status mean higher volatility and funding sensitivity — suitable mainly for investors who tolerate elevated risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
